Agenus (NASDAQ:AGEN) Shares Cross Above 200 Day Moving Average – What’s Next?

Agenus Inc. (NASDAQ:AGEN)’s stock price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $4.15 and traded as high as $8.07. Agenus shares last traded at $7.67, with a volume of 772,906 shares traded.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. B. Riley Financial reissued a “buy” rating and set a $14.00 price target (up from $8.00) on shares of Agenus in a research report on Thursday, July 30th. Weiss Ratings lowered Agenus from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday. Wall Street Zen cut Agenus from a “strong-buy” rating to a “hold” rating in a report on Monday, August 17th. Finally, Zacks Research downgraded Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $19.50.

Agenus Trading Down 0.6%

The company’s 50-day moving average is $5.49 and its 200-day moving average is $4.19. The firm has a market cap of $374.12 million, a price-to-earnings ratio of 3.22 and a beta of 1.41.

Agenus (NASDAQ:AGEN) last announced its quarterly earnings data on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). Agenus had a net margin of 69.33% and a negative return on equity of 47.68%. The firm had revenue of $34.52 million for the quarter, compared to analyst estimates of $34.00 million. Equities research analysts forecast that Agenus Inc. will post -0.28 EPS for the current year.

Hedge Funds Weigh In On Agenus

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in Agenus by 1.5% in the third quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock valued at $9,893,000 after buying an additional 36,983 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Agenus by 721.1% in the fourth quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after acquiring an additional 477,346 shares during the last quarter. AQR Capital Management LLC lifted its holdings in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after acquiring an additional 427,604 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Agenus in the 2nd quarter valued at approximately $1,976,000. Finally, Bank of America Corp DE boosted its stake in shares of Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after purchasing an additional 220,327 shares in the last quarter. Institutional investors and hedge funds own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.